An Observational Post-Authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto®). "ROSE"

Completed

Phase N/A Results N/A

Main Contacts

Name Phone E-mail
Alison Evans, PhD Contact 00442380408600 alison.evans@dsru.org

Contacts by Location

Drug Safety Research Unit Southampton, Hampshire, United Kingdom Unknown_status_icon
Alison Evans, PhD Contact 00442380408600 alison.evans@dsru.org